<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02891655</url>
  </required_header>
  <id_info>
    <org_study_id>EGN_2016_6</org_study_id>
    <nct_id>NCT02891655</nct_id>
  </id_info>
  <brief_title>KERatoconus and Metalloproteinases InvesTigation</brief_title>
  <acronym>KERMIT</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      Corneal stromal thinning observed in keratoconic eyes could result from an increased&#xD;
      synthesis of MMP at the level of the anterior stroma and the corneal epithelium induced by an&#xD;
      overexpression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) and Galectin-3&#xD;
      by epithelial cells. A differential expression of EMMPRIN, Galectin-3 and metalloproteinases&#xD;
      (MMP) may be observed between the apex of the keratoconus and the peripheral cornea.&#xD;
      Highlighting the implication of EMMPRIN and Galectin-3 could lead to the development of&#xD;
      specific inhibitors to slow or to stop keratoconus evolution.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2016</start_date>
  <completion_date type="Actual">November 26, 2020</completion_date>
  <primary_completion_date type="Actual">June 26, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) in epithelial cells</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>surgery for keratoconus</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>refractive surgery (control patients)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immuno-histo-chemical analysis</intervention_name>
    <description>in vitro immuno-histo-chemical analysis of corneal epithelium</description>
    <arm_group_label>refractive surgery (control patients)</arm_group_label>
    <arm_group_label>surgery for keratoconus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with keratoconus and controls subjects without keratoconus&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 18 years old&#xD;
&#xD;
          -  Patient with keratoconus undergoing corneal collagen cross-linking (epithelium-off&#xD;
             methods)&#xD;
&#xD;
          -  Patient with keratoconus undergoing his first corneal graft for optical indication&#xD;
             (control)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with keratoconus undergoing corneal graft for tectonic indication&#xD;
&#xD;
          -  Patient undergoing corneal refractive surgery (refractive photokeratectomy) with a&#xD;
             normal topography, a normal slit lamp examination and no previous ophthalmic condition&#xD;
             (control)&#xD;
&#xD;
          -  pregnant or breast feeding patient&#xD;
&#xD;
          -  patient under judiciary protection&#xD;
&#xD;
          -  patient opposition to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric GABISON, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation OPH A de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondation Opthalmologique A de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>December 9, 2020</last_update_submitted>
  <last_update_submitted_qc>December 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

